我們已在上線! 進一步了解
ONCR

Oncorus

已下市

ONCR已於2023年6月20日下市。

 

公司簡介: Oncorus Inc is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The company is in the process of developing intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. Its pipeline product includes ONCR-021 and ONCR-788 which are based on coxsackievirus A21 or CVA21, and Seneca Valley Virus, or SVV, respectively.

員工: 64

新聞

正面
中性
負面
市場情緒 3個月
正面 0%
中性 0%
負面 0%

我們尚未收到任何關於ONCR的最新新聞文章。

價格圖表採用Lightweight Charts™實作